secwatch.observer — SEC 8-K summary
======================================

Issuer:     PTC THERAPEUTICS, INC. (PTCT)
CIK:        0001070081
Form:       8-K
Filed at:   2024-11-07T23:59:59+00:00
Accession:  0001070081-24-000021
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PTC Therapeutics Q3 revenue $196.8M, raises FY2024 guidance to $750-800M, multiple FDA submissions
--------------------------------------------------------------------------------

- Q3 total revenue $196.8M (vs $196.6M YoY); DMD franchise $124M (Translarna $72M, Emflaza $52M).
- Net loss narrowed to $106.7M from $133M; cash & securities $1.01B.
- FY2024 revenue guidance raised to $750-800M; GAAP R&D+SG&A $740-835M.
- FDA accepted sepiapterin NDA (PKU) with action date July 29, 2025; AADC gene therapy BLA action Nov 13, 2024.
- Plans to submit vatiquinone NDA for Friedreich ataxia in Dec 2024; fast track for PTC518 Huntington's.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1070081/000107008124000021/0001070081-24-000021-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1070081/000107008124000021/tmb-20241107x8k.htm
  HTML page:      https://secwatch.observer/filing/0001070081-24-000021

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer